Literature DB >> 33237281

Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation.

Mark J Ratain1,2, Javid J Moslehi3, Allen S Lichter2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33237281     DOI： 10.1001/jamaoncol.2020.5742

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Ibrutinib's off-target mechanism: cause for dose optimization.

Authors:  Sara M Zimmerman; Cody J Peer; William D Figg
Journal:  Cancer Biol Ther       Date:  2021-10-10       Impact factor: 4.875

2.  Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.

Authors:  Eric D Eisenmann; Qiang Fu; Elizabeth M Muhowski; Yan Jin; Muhammad Erfan Uddin; Dominique A Garrison; Robert H Weber; Jennifer Woyach; John C Byrd; Alex Sparreboom; Sharyn D Baker
Journal:  Cancer Res Commun       Date:  2021-11-09

Review 3.  Cardiac complications associated with hematopoietic stem-cell transplantation.

Authors:  Akihiro Ohmoto; Shigeo Fuji
Journal:  Bone Marrow Transplant       Date:  2021-08-11       Impact factor: 5.174
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.